PhRMA finds 785 drugs in development for older Americans
New medicines in the pipeline for Alzheimer's disease, osteoporosis, arthritis and Parkinson's disease are among the many promising treatments in development for diseases of aging, according to a new survey released by the Washington-based Pharmaceutical Research and Manufacturers of America.
New medicines in the pipeline for Alzheimer's disease, osteoporosis, arthritis and Parkinson's disease are among the many promising treatments in development for diseases of aging, according to a new survey released by the Washington-based Pharmaceutical Research and Manufacturers of America.
The latest survey highlights the work of 120 pharma and biotech companies:
•Â Forty-four drugs are in development for respiratory and lung disorders, the fourth leading cause of death among the elderly.
•Â Twenty-three are in development for diabetes, the sixth leading cause of death among people 65 and older.
•Â Twenty-one are in the pipeline for Alzheimer's disease, which will afflict 14 million Americans by mid-century unless a cure or method of prevention is found.
All of these potential medicines are in clinical trials or awaiting final approval by the Food and Drug Administration.
Said Alan F. Holmer, president of PhRMA, "Our aging populace underlines the need for prescription drug coverage for seniors, who expect and deserve access to the fruits of medical research. Medicare drug coverage must be crafted in a way that gives seniors access to the medicines of today and provides incentives for companies to discover the medicines of tomorrow." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
